ExpreS2ion Biotech announces clinical trial update for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ExpreS2ion Biotech announces clinical trial update for the PamVac (Placental Malaria Vaccine) phase I study

PamVac (Placental Malaria Vaccine) phase I study ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical trial of the placental malaria vaccine candidate, PAMVAC. Due to the trial’s staggered approach, the second evaluation allows initiation of the phase Ib clinical trial to be conducted in Benin, Africa. The clinical trial is funded by the EU under the FP7 program and coordinated by associate professor Morten A Nielsen at University of Copenhagen in collaboration with University of Tübingen, Université d'Abomey-Calavi, European Vaccine Initiative, Institut de Recherche pour le Développement, and ExpreS2ion Biotech. Placental malaria Women, who have acquired immunity against malaria during childhood, nevertheless become susceptible to malaria again during their first pregnancies. Parasites accumulate in the placenta, where a combination of altered blood flow and expression of chondroitin sulphate A (CSA) provides a new niche for parasites to sequester. Malaria in pregnant women thus constitutes a major health problem in areas south of the Sahara, manifesting as severe disease, anemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. Placental malaria has been estimated by the WHO to be responsible for 20,000 maternal and 200,000 infant deaths annually. Fortunately, women acquire immunity against placental malaria, and in malaria endemic areas the average birth weight is significantly higher among second- and third- compared to first-born babies. This relatively fast development of protection has raised the hope that a vaccine for placental malaria can be developed. Worldwide collaborations on the vaccine In 2003 Professor Ali Salanti and others at University of Copenhagen discovered the antigen VAR2CSA, which enable parasite accumulation in the placenta. Since then collaborations with many groups around the world, especially Professor Philippe Deloron at Institut de Recherche pour le Développement, France, has enabled the preclinical development of the vaccine. The European Vaccine Initiative has been instrumental in the mobilization of funds and in the clinical development of the vaccine, where its fast-track strategy is implemented allowing a more efficient development of the vaccine candidate. The phase Ia clinical trial is led by Professor Benjamin Mordmüller (University of Tübingen) and the phase Ib trial is led by Dr. Saadou Issifou (Institut de Recherche Clinique du Bénin). Preparations for a Phase II clinical trial are led by Professor Achille Massougbodji (Université d'Abomey-Calavi), Dr Jean-Philippe Chippaux (Institut de Recherche pour le Developement) and Dr Adrian JF Luty (Institut de Recherche pour le Développement). ExpreS2ion Biotech contributed to the collaboration through supply of protein antigen variants for selection of the best candidate, as well as developing the production cell line and manufacturing process. Copenhagen University obtained a license to the ExpreS2 system for the production of the PAMVAC vaccine antigen. The clinical trial To induce high concentrations of specific IgGs, subjects will receive escalating doses of PAMVAC vaccine antigen adjuvanted with Alhydrogel, GLA-emulsion or GLA -liposome. Three injections with the same dosage and adjuvant will be done, each 28 days apart (Day 0, 28 and 56). Dosage escalation will be staggered to ensure safety during the trial. Control subjects will receive physiological saline instead of the vaccine. The clinical trial is a phase I, staggered, two-center, dose-escalation trial. The trial will be conducted in two stages. The first in Germany (first in man and dose escalation) and the second in a malaria-endemic area in the target group (randomized, controlled, dose-finding). First in man administration and dose escalation from 20 to 50 μg per injection of PAMVAC adjuvanted with Alhydrogel, GLA-emulsion or GLA-liposome will be done in healthy, malaria-naïve adults in Germany (phase 1a). Subsequently, PAMVAC will be administered to healthy, lifelong malaria exposed nulligravid women in Benin at doses of 50 and 100 μg, adjuvanted with Alhydrogel and GLA-emulsion (phase Ib). In Benin, one group will receive a placebo control (physiological saline). Allocation to placebo, PAMVAC+Alhydrogel or PAMVAC+GLA-emulsion, will be randomized. Each dose-escalation is conditional on a positive safety assessment by an independent safety monitoring board (ISMB) and sponsor approval. One individual of each PAMVAC-adjuvant combination will serve as sentinel. The sentinel will be injected one day before the rest of the group. There will be a minimum of four weeks stagger between the first immunizations in phase Ia and phase Ib. Grant Funding: The PAMCPH project supporting the cGMP manufacture of the vaccine was funded by the German Federal Ministry of Education and Research (BMBF) through Kreditanstalt für Wiederaufbau (KfW) and European Vaccine Initiative, the PlacMalVac (University of Copenhagen, Denmark) project supporting the cGMP manufacture, clinical trial and preparation for phase II was funded by the European Union Seventh Framework Programme, FP7-HEALTH-2012-INNOVATION under grant agreement n° 304815 (http://ec.europa.eu/research/fp7/index_en.cfm?pg=health), the preclinical development of the vaccine was supported by Danish Advanced Technology Foundation under grant number 005-2011-1 (http://innovationsfonden.dk/en). CEO Steen Klysner comments “This is a very exciting project and we now look forward to the outcome of the trial. I also note that this further validates the regulatory acceptance of the ExpreS2 platform under GMP for clinical use" For further information about ExpreS2ion, please contact: Steen Klysner, CEO Telephone: +45 2062 9908 E-mail: sk@expres2ionbio.com This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CET, July the 28th 2016. About ExpreS2ion ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS2 platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 34

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 86

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 16

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 427

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 372

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 42

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 55

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading

Top 5 Most Recently Viewed Articles

E-commerce Brands Make Striking Debut at Fashion Week

Updated Category News Views 96

E-commerce Brands Shine at Fashion Week In an exciting turn for the fashion world, online powerhouses Coofandy and Ekouaer have made a memorable entrance at New York Fashion Week (NYFW). They brought along the star power of supermodels Helena Christensen and Sean O'Pry to help spotlight their brands. Coofandy, known for its stylish menswear, and Ekouaer, which specializes...

Continue Reading
Tallinna Vesi Plans To Adjust Water Service Prices in 2025

Updated Category News Views 182

Tallinna Vesi Plans Adjustment of Water Supply Prices for 2025 Tallinna Vesi has submitted an application to change the prices of its water supply services, pending approval from the Competition Authority. The changes, projected to take effect in 2025, are rooted in legal requirements to standardize pricing for both private and business customers. This initiative aims to...

Continue Reading
Investor Insights: Bullish Moves in PDD Holdings Options

Updated Category News Views 131

Unusual Options Activity in PDD Holdings In recent trading sessions, investors with substantial capital have taken a bullish stance toward PDD Holdings (NASDAQ: PDD). This behavior is drawing significant attention in the financial landscape, suggesting that noteworthy changes may be on the horizon. Our latest findings highlight this trend and delve into the implications...

Continue Reading
AI and Software Spending Surge: Insights for Businesses in 2025

Updated Category News Views 426

AI and Software Spending Trends Shaping 2025 As companies continue to adapt to evolving market demands, one thing has become abundantly clear: software spending is on the rise. The landscape of corporate technology acquisitions has changed dramatically, with a reported increase of 10% in software spending in recent times. This growth mirrors the increasing integration of...

Continue Reading
Unleashing Summer Fun: Kinder Chocolate and Paul George Unite

Updated Category News Views 227

Refreshing Summer with Kinder Chocolate's Brand Campaign In a delightful move that captures the essence of summer joy, Kinder Chocolate is launching a vibrant campaign called Pass The Fun. With an exciting collaboration featuring NBA All-Star Paul George, the campaign promises to spark joyful moments for families and kids through basketball this summer. This initiative...

Continue Reading